4/8
07:18 am
kymr
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]
4/8
07:00 am
kymr
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Low
Report
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
3/8
10:14 am
kymr
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/8
10:00 am
kymr
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
Low
Report
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
3/4
11:38 pm
kymr
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) [Yahoo! Finance]
Low
Report
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) [Yahoo! Finance]
3/3
07:31 am
kymr
Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher [Yahoo! Finance]
Low
Report
Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher [Yahoo! Finance]
3/1
09:03 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Truist Financial Co. from $41.00 to $54.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Truist Financial Co. from $41.00 to $54.00. They now have a "buy" rating on the stock.
2/28
07:10 am
kymr
Kymera Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/28
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
2/27
10:55 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Piper Sandler from $39.00 to $56.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Piper Sandler from $39.00 to $56.00. They now have an "overweight" rating on the stock.
2/24
10:15 am
kymr
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
Medium
Report
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
2/23
01:09 pm
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $34.00 to $47.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $34.00 to $47.00. They now have an "overweight" rating on the stock.
2/23
09:00 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $55.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $55.00. They now have a "buy" rating on the stock.
2/22
07:44 am
kymr
Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/22
07:06 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
2/22
07:00 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
2/15
07:17 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
2/15
07:00 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
2/10
03:14 am
kymr
Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc [Yahoo! Finance]
Medium
Report
Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc [Yahoo! Finance]
1/31
07:12 am
kymr
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference [Yahoo! Finance]
Medium
Report
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference [Yahoo! Finance]
1/31
07:00 am
kymr
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
Medium
Report
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
1/24
12:34 am
kymr
Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc [Yahoo! Finance]
Medium
Report
Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc [Yahoo! Finance]